Leerink Partnrs Expects Lower Earnings for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for Henry Schein in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $1.14 per share for the quarter, down from their previous estimate of $1.19. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Leerink Partnrs also issued estimates for Henry Schein’s Q3 2025 earnings at $1.26 EPS.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.66 earnings per share.

A number of other equities analysts also recently commented on the company. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Barrington Research restated an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a research note on Wednesday. UBS Group reduced their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Finally, Wells Fargo & Company assumed coverage on shares of Henry Schein in a research report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $72.12 on Friday. The company has a 50-day moving average price of $74.35 and a 200-day moving average price of $72.42. The company has a market cap of $8.99 billion, a price-to-earnings ratio of 29.68, a price-to-earnings-growth ratio of 2.13 and a beta of 0.91. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein has a 12 month low of $63.67 and a 12 month high of $82.49.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently made changes to their positions in HSIC. Jefferies Financial Group Inc. increased its stake in Henry Schein by 98.8% during the fourth quarter. Jefferies Financial Group Inc. now owns 83,100 shares of the company’s stock worth $5,751,000 after acquiring an additional 41,300 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Henry Schein by 97.2% during the 4th quarter. Mackenzie Financial Corp now owns 8,819 shares of the company’s stock valued at $610,000 after buying an additional 4,348 shares during the period. Forum Financial Management LP bought a new stake in Henry Schein in the fourth quarter worth $221,000. Toronto Dominion Bank boosted its stake in Henry Schein by 6.7% during the fourth quarter. Toronto Dominion Bank now owns 66,997 shares of the company’s stock worth $4,636,000 after buying an additional 4,218 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Henry Schein during the fourth quarter valued at $194,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.